In 2013 the World Health Organization reported 8.7 million incident cases of active tuberculosis worldwide and 1.4 million attributable deaths [1] . In addition, an estimated one-third of the world's population harbor Mycobacterium tuberculosis in an asymptomatic state called latent M. tuberculosis infection, or latent tuberculosis. Although most healthy individuals with latent tuberculosis are able to control infection, various coexistent conditions, including silicosis, diabetes, renal disease, malnutrition, and immunosuppressive medications (ie, steroids and tumor necrosis factor α inhibitors), hasten the progression to active tuberculosis disease [2] . Human immunodeficiency virus (HIV) is among the most important risk factors to date, because the 10% lifetime risk of progression to active tuberculosis climbs to a 5%-10% annual risk with HIV coinfection [3] .
Natural history HIV cohorts have highlighted the importance of CD4 + T cells in controlling tuberculosis. As CD4 + T cells decline, the incidence and extrapulmonary dissemination of tuberculosis rises [4, 5] . During acute HIV infection, M. tuberculosis-specific CD4 + T cells are preferentially depleted in peripheral blood [6, 7] . Although M. tuberculosis-specific polyfunctional CD4 + T-cell responses are largely preserved in HIV-infected individuals with latent tuberculosis, the degree of HIV viremia correlates inversely with their capacity to produce interleukin 2 [8] . Interestingly, even with preservation of CD4 + T-cell counts, the risk of developing active tuberculosis is higher among HIV-infected individuals than among their HIV-uninfected counterparts [9] . This led us to hypothesize that defective M. tuberculosis-specific CD8 + T-cell immunity may also contribute to the heightened risk of tuberculosis progression in HIV-infected individuals with latent tuberculosis. Relatively little is known about M. tuberculosis-specific CD8 + T-cell immunity in humans. Murine studies have demonstrated a 10-fold increase in M. tuberculosis in the lungs of infected mice after antibody-mediated depletion of CD8 + T cells or with infection of CD8 + T cell-deficient mice [10] . Among macaques with latent tuberculosis coinfected with simian immunodeficiency virus, those with fewer M. tuberculosis-specific (interferon [IFN] γ + CD8 + T cells progressed more rapidly to active tuberculosis [11] . Studies of individuals with latent tuberculosis treated with tumor necrosis factor α inhibitors highlight the importance of M. tuberculosis-specific CD8 + T-cell cytolytic granule production in maintaining latency [12] . Although defects in HIV-specific degranulation and T-helper 1 responses have been reported to be associated with uncontrolled HIV viremia [13] , little is known about the effects of HIV infection on M. tuberculosis-specific CD8 + T-cell immunity.
To identify potential HIV-induced defects in CD8 + T-cell immunity in latent tuberculosis, we sought differences in M. tuberculosis-specific CD8 + T-cell functions in HIVinfected and HIV-uninfected individuals with latent tuberculosis from tuberculosis-endemic regions in South Africa.
Specifically, we evaluated the effect of HIV coinfection on M. tuberculosis-specific CD8 + T-cell IFN-γ production, degranulation, and proliferative capacity.
MATERIALS AND METHODS

Study Subjects and Sample Collection
Men and women aged ≥18 years were recruited in the Western Cape province of South Africa at the South African Tuberculosis Vaccine Initiative field site in the Worcester area, located 110 km outside Cape Town (Supplementary Table 1 ). Individuals were clinically evaluated for evidence of active tuberculosis disease (ie, cough, weight loss, fever, and night sweats) at study entry. Those with prior diagnosis and/or symptoms of active tuberculosis and those previously treated for tuberculosis were excluded. Peripheral blood was collected in Vacutainer tubes. To evaluate for latent tuberculosis, we assayed Peripheral blood mononuclear cells (PBMCs) from HIV-infected individuals, using QuantiFER-ON-TB Gold In-Tube (QFT; Cellestis) and intracellular staining for IFN-γ followed by flow cytometry. To assess PBMCs from HIV-uninfected individuals, we used intracellular staining for IFN-γ followed by flow cytometry. Individuals positive for QFT or intracellular IFN-γ were defined as having latent tuberculosis, and those with negative results were excluded. The Alere Determine HIV Combo test was used to screen for HIV-1 and HIV-2 infection. PBMCs were isolated using Ficoll-Hypaque (Sigma-Aldrich) in South Africa and cryopreserved at −180°C anywhere from 4 months to 4 years post-collection. Oregon Green (OG) proliferation assays using fresh PBMCs were conducted in Cape Town, South Africa, at the South African Tuberculosis Vaccine Initiative laboratories. The rest of the cell stimulations and flow cytometry were performed at the Emory Vaccine Center in Atlanta, Georgia, using cryopreserved PBMCs shipped from South Africa to the Emory Vaccine Center.
Proliferation Assay
Freshly isolated PBMCs were labeled with Cell Trace OG 488 carboxylic acid diacetate succinimidyl ester (OG; Life Technologies) and incubated for 6 days with ESAT-6/CFP-10 peptide pools, Staphylococcus enterotoxin B (SEB), or left nonstimulated. Cells were stained with LIVE/DEAD Fixable Violet Dead Cell Stain (Vivid; Life Technologies), fixed with FACS Lysing Solution (BD Biosciences), and stained with anti-CD4 Qdot605 (S3.5; Life Technologies), anti-CD3 allophycocyanin-H7 (SK7), and anti-CD8 peridinin chlorphyll protein (PerCP)-cyanine (Cy) 5.5 (SK-1) from BD Biosciences.
PBMC Stimulation and Flow Cytometry
Thawed PBMC were rested overnight at 37°C and 5% carbon dioxide in Roswell Park Memorial Institute 1640 medium (Lonza) with 10% fetal bovine serum, 2 mmol/L glutamine, 100 IU/mL penicillin, and 100 µg/mL streptomycin. The lymphocyte viability was 75%-95%, as determined by the Countess Automated Cell Counter (Invitrogen Life Technologies). The PBMCs were prestained with CD107a-phycoerythrin Cy7 (BD Biosciences) for 1 hour, after which 2 × 10 6 PBMCs were each subjected to (1) no stimulation, (2) stimulation with ESAT-6/CFP-10 peptide pools of 15 mer overlapping with 11 amino acids (10 µg/mL; Genemed Synthesis), or (3) SEB (5 µg/mL), as described elsewhere [14] . A costimulatory CD28/49d cocktail (1 µg/mL; BD Biosciences), brefeldin A, and monensin (10 µg/mL) were added at the time of stimulation, followed by incubation for 18 hours. The PBMCs were stained with the LIVE/DEAD kit (Invitrogen Life Technologies) and surface stained with CD4-peridinin chlorophyll (BD Biosciences) and CD8-BV570 (BioLegend). Cells were permeabilized with a Cytofix/Cytoperm Kit (BD Biosciences) and stained with IFN-γ-Pacific blue (BD Biosciences) and CD3-allophycocyanin-Cy7 (BioLegend), fixed using 1% paraformaldehyde, and samples were acquired on an LSR-II system (BD Biosciences).
Data Analysis
Flow cytometry data were analyzed using FlowJo software (version 9). GraphPad Prism software (version 6.0) was used for statistical analysis. Nonstimulated IFN-γ and CD107a responses were subtracted from all ESAT-6/CFP-10 and SEB-stimulated PBMC responses. The Mann-Whitney U test was used to evaluate differences between HIV-infected and HIV-uninfected individuals with latent tuberculosis. Differences were considered statistically significant at P < .05 (2 tailed).
Ethical Approval
This study was approved by the Emory University Institutional Review Board, the Human Research Ethics Committee of the University of Cape Town, and the Western Cape Department of Health. All subjects provided written informed consent before participation.
RESULTS
Study Participants
To evaluate the effect of HIV infection on M. tuberculosisspecific CD8 + T-cell function, we recruited 20 HIV-infected and 22 HIV-uninfected individuals with latent tuberculosis from the Western Cape province, South Africa (Supplementary Table 1 Figure 2D and 2E ) . The proliferative capacity of ESAT-6/ CFP-10-specific CD8 + T cells was significantly lower in the HIV-infected group (P < .001) than in the HIV-uninfected group. In contrast, there were no significant differences in SEB-induced proliferation between the 2 groups ( Figure 2F ; P = .09). These data indicate that coinfection with HIV impairs the proliferative capacities of M. tuberculosis-specific CD8 + T cells in latent tuberculosis. T-cell help due to deficiencies in interleukin 2 or in CD40-CD40L interactions [8] . SEB-specific CD107a + CD8 + T-cell frequencies were higher in HIV-infected than in HIV-uninfected individuals, suggesting that HIV immune activation may reduce their degranulation threshold. We also tested responses to a cytomegalovirus, Epstein-Barr virus, and influenza virus (CEF) peptide pool consisting of CD8 epitopes; no significant differences were observed between HIV-infected and uninfected groups to CEF, although not all subjects showed measurable responses to these peptides (data not shown).
DISCUSSION
Our results provide new insights into the role of M. tuberculosis-specific CD8 + T cells in maintaining latent tuberculosis and suggest that HIV coinfection may perturb immune control by impairing the capacity of antigen-specific CD8 + T cells to contain latent infection. The relatively small sample size of this crosssectional study precluded examination of the effects of potential confounders (eg, CD4 + T-cell count and viral load) on immunological function. Furthermore, the lack of long-term follow-up of the latently infected subjects did not allow us to determine whether any of them developed tuberculosis after study enrollment. Nevertheless, despite these limitations, our data underscore the need to further evaluate M. tuberculosis-specific CD8 + T-cell degranulation, proliferation, and cytolytic activity in larger prospective cohorts and determine whether deficits in antigen-specific CD8 + T-cell functions evolve with HIV disease progression by enrolling participants across a broader range of CD4 + T-cell counts and plasma HIV loads. + T cells or proliferating CD8 + T cells between HIV-uninfected and HIV-infected groups were assessed using the Mann-Whitney test; differences were considered statistically significant at P < .05 (2 tailed). Abbreviations: IFN, interferon; OG, Oregon Green; VIVID, violet dead cell stain.
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